Get Help Sign In


IDT Acquires Swift Biosciences, a Pioneer in the Development of Next-Generation Sequencing (NGS) Library Preparation Genomics Kits for Academic, Translational, and Clinical Research

Mar 11, 2021
Combining IDT’s high-quality NGS products with Swift’s broad portfolio of library preparation and enrichment products will be transformative for enabling scientists to conduct research more efficiently
CORALVILLE, Iowa (March 11, 2021)Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, announced today the acquisition of Swift Biosciences, a pioneer in the development of Next-Generation Sequencing (NGS) library preparation genomics kits for academic, translational, and clinical research.  IDT is a leader in developing and manufacturing nucleic acid products for academic and commercial research, agriculture, medical diagnostics, pharmaceutical development, and synthetic biology.  Swift develops and commercializes NGS Library Prep Kits that maximize data output, provide comprehensive coverage, and reduce sequencing costs.  

”We have been impressed with the Swift products and organizational talent,” said IDT President Trey Martin.  “Swift’s research tools are being used for cancer, inherited disease, and other health applications, as well as research in agrigenomics, metagenomics, and the biotech/pharmaceutical industry.  Their broad portfolio of library preparation and enrichment products are highly complementary to IDT’s existing NGS product line, giving us an increased ability to provide gold standard offerings to researchers and to be well positioned for future growth.”

“The synergies between IDT and Swift make this acquisition an excellent fit,” commented Nathan Wood, President and CEO of Swift. “Since entering the NGS market in 2013, Swift’s mission has been to provide research tools for long term improvements in the health of individuals and their communities all around the world.  IDT has the commercial engine, operational tools, and resources to catalyze these efforts.”

Swift associates and products will transition into IDT while continuing to operate from its existing facilities in Ann Arbor, Michigan. Financial terms of the transaction were not disclosed.

IDT is an operating company within Danaher Corporation’s (NYSE: DHR) Life Sciences platform. For more information, please visit 

Follow IDT on Twitter @idtdna for real-time updates and insights.

About IDT
Integrated DNA Technologies, Inc. (IDT)
develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP services, IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as the industry leader in custom nucleic acid manufacture, serving over 130,000 life sciences researchers. IDT was founded in 1987 and has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Research Triangle Park, North Carolina, USA; Leuven, Belgium; and Singapore. For more information, please visit

Media Contact
IDT Public Relations
800-328-2661 (USA & Canada)
+1 319-626-8400 (outside USA)  


Learn about IDT's role in the fight against COVID-19

Media and PR

For media inquiries please contact IDT Public Relations,

*RUO—For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend for these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.